Warning letter
Auro Pharmacies, Inc., dba Central Drugs Compounding Pharmacy: warning letter of Jun 3, 2020
FDA warning letter 608369 · Division of Pharmaceutical Quality Operations IV
Key facts
| Reference number | 608369 |
|---|---|
| Company | Auro Pharmacies, Inc., dba Central Drugs Compounding Pharmacy |
| Subject | CGMP/Drug Products/Adulterated |
| Issue date | Jun 3, 2020 |
| Posted date | Jun 30, 2020 |
| Issuing office | Division of Pharmaceutical Quality Operations IV |
| Product type | Drugs |
| CFR sections cited | 201.115, 211.58, 200.10(b), 211.84(d)(6), 211.166(a), 210.1(b) |
| Inspection city | La Habra |
| Inspection ZIP | 90631 |
| Inspection start date | Jul 9, 2018 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: